Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05900531 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 in Healthy Overweight/Obese Volunteers
A Phase 1 study, sponsored by Kallyope.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT05900531: Completed Phase 1 study, sponsored by Kallyope.
NCT05900531 is a Phase 1 study that has completed, run by Kallyope. The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05900531, a Phase 1 study, has completed, sponsored by Kallyope.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
This is a multiple dose study to evaluate the safety, tolerability, PK, and PD of K-757 alone, in combination with sitagliptin, or in combination with K-833.
Interventions
- DRUG K-757 and K-833
- DRUG K-757
- DRUG K-757 and open-label sitagliptin
- DRUG Matching placebo to K-757
- DRUG Matching placebo to K-757 and matching placebo to K-833
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2022-09-21 |
| Est. Completion | 2023-05-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05900531
The ClinicalTrials.gov registry entry for NCT05900531 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kallyope, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which K-757 and K-833 is the first listed.
NCT05900531 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05900531 about?
NCT05900531 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 in Healthy Overweight/Obese Volunteers". This is a multiple dose study to evaluate the safety, tolerability, PK, and PD of K-757 alone, in combination with sitagliptin, or in combination with K-833.
What is the current status of trial NCT05900531?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2022-09-21. Estimated completion is 2023-05-31.
What interventions are being tested in trial NCT05900531?
The interventions under investigation include: K-757 and K-833 (DRUG), K-757 (DRUG), K-757 and open-label sitagliptin (DRUG), Matching placebo to K-757 (DRUG), Matching placebo to K-757 and matching placebo to K-833 (DRUG).
Who is sponsoring clinical trial NCT05900531?
This trial is sponsored by Kallyope, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.